Analysis on vaccination status and safety of 13 valent pneumococcal conjugate vaccine among children born in a certain district of Beijing from 2017 to 2022
Objective To understand the vaccination rates of each dose of the 13-valent pneumococcal conjugate vaccine(PCV13)for school-age children in a certain district of Beijing,as well as the classified reporting rate of suspected event following immunization(AEFI).Methods Based on the"Beijing Vaccination Management System"to analyze the PCV13 vaccination information of children in the birth cohort from 2017 to 2022,and calculate the vaccination rate.Obtain vaccine AEFI report data through the"China Disease Prevention and Control Information System",and calculate the AEFI classification report rate.Results The first dose PCV13 vaccination rate increased from 7.90％in 2017 to 41.96％in 2021(x2trend=5474.34,P＜0.01).The total reporting rate of AEFI was 7.47/10 000(52 cases),with general reactions and abnormal reactions being 7.07/10 000(49 cases)and 4.33/10 000(3 cases),respectively.Fever,local redness and swelling,local induration,and allergic rash were 5.17/10 000(36 cases),2.30/10 000(16 cases),0.86/10 000(6 cases),and 0.43/10 000(3 cases),respectively.Conclusion From 2017 to 2021,the PCV13 vaccination rate among children in the birth cohort in a certain district of Beijing showed an upward trend.AEFI is mainly characterized by general reactions,with fever being the most common clinical manifestation.It is necessary to improve the sensitivity of AEFI monitoring in outpatient clinics with a large number of vaccinations and a low frequency of outpatient days in daily life.
13-valent pneumococcal conjugate vaccineVaccination rateSuspected abnormal reaction to vaccination
NETL
NSTL
万方数据
